Introduction
============

Triple-negative breast cancer (TNBC) is defined as a subtype of breast cancer which lacks expression of estrogen receptor (ER) and progesterone receptor (PR) and demonstrates no amplification of human epidermal growth factor receptor 2 (HER2). This subset accounts for \~12%--17% of all invasive breast cancers.[@b1-ott-11-4105] TNBC is more frequently diagnosed in younger women and behaves more aggressively in clinical behaviors. Patients with TNBC are more likely to develop relapse and visceral metastasis than other subtypes of breast cancer.[@b2-ott-11-4105]--[@b5-ott-11-4105] Lacking molecular targets, patients diagnosed with TNBC cannot be treated with endocrine therapy or HER2-targeted therapy. Chemotherapy is currently the main adjuvant treatment for TNBC patients.[@b1-ott-11-4105] Unfortunately, many tumors are resistant to chemotherapy and relapse or metastasize quickly after adjuvant treatment.[@b6-ott-11-4105],[@b7-ott-11-4105] Up to date, TNBC is still a disease with poor outcome and limited treatment options. Hence, it is urgent and necessary to explore novel therapeutic targets for TNBC.

In this study, we tried to detect novel indicators of poor prognosis in TNBC patients and endeavor to provide potential therapeutic targets for this challenging disease. To detect the differentially expressed genes (DEGs) between TNBC and healthy human breast tissue, bioinformatics methods were used to analyze the gene expression profiling data downloaded from the Gene Expression Omnibus (GEO) database. Gene Ontology (GO) functional annotation analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed for the screened DEGs. Then, we established a protein--protein interaction (PPI) network to identify hub genes related to TNBC. The survival analysis of these hub genes was performed using the online database Kaplan--Meier plotter.

Materials and methods
=====================

Data source
-----------

The gene expression datasets analyzed in this study were obtained from the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>). A total of 1,821 series about human breast cancer were retrieved from the database. After a careful review, three gene expression profiles (GSE38959, GSE45827, and GSE65194) were selected. Among them, GSE38959 was based on the Agilent GPL4133 platform (Agilent-014850 Whole Human Genome Microarray 4×44K G4112F), and GSE45827 and GSE65194 were based on platform GPL570 (\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array). All of the data were freely available online, and this study did not involve any experiment on humans or animals performed by any of the authors.

Data processing of DEGs
-----------------------

The GEO2R online analysis tool (<https://www.ncbi.nlm.nih.gov/geo/geo2r/>) was used to detect the DEGs between TNBC and normal samples, and the adjusted *P*-value and \|logFC\| were calculated. Genes that met the cutoff criteria, adjusted *P*\<0.05 and \|logFC\|≥2.0, were considered as DEGs. Statistical analysis was carried out for each dataset, and the intersecting part was identified using the Venn diagram webtool ([bioinformatics.psb.ugent.be/webtools/Venn/](http://bioinformatics.psb.ugent.be/webtools/Venn/)).

GO and KEGG pathway analysis of DEGs
------------------------------------

GO analysis is a common useful method for large scale functional enrichment research; gene functions can be classified into biological process (BP), molecular function (MF), and cellular component (CC). KEGG is a widely used database which stores a lot of data about genomes, biological pathways, diseases, chemical substances, and drugs. GO annotation analysis and KEGG pathway enrichment analysis of DEGs in this study was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) tools (<https://david.ncifcrf.gov/>). *P*\<0.01 and gene counts≥10 were considered statistically significant.

PPI network construction and hub gene identification
----------------------------------------------------

The Search Tool for the Retrieval of Interacting Genes (STRING) database (<http://string-db.org/>) is designed to analyze the PPI information. To evaluate the potential PPI relationship, the DEGs identified previously were mapped to the STRING database. The PPI pairs were extracted with a combined score\>0.4. Subsequently, the PPI network was visualized by Cytoscape software ([www.cytoscape.org/](http://www.cytoscape.org/)). Nodes with higher degree of connectivity tend to be more essential in maintaining the stability of the entire network. CytoHubba, a plugin in cytoscape, was used to calculate the degree of each protein node. In our study, the top ten genes were identified as hub genes.

Survival analysis of hub genes
------------------------------

The Kaplan--Meier plotter (<http://kmplot.com/analysis/>) is an online tool applied to assess the effect of 54,675 genes on survival using 10,461 cancer samples (5,143 breast, 1,816 ovarian, 2,437 lung, and 1,065 gastric cancer). The Kaplan--Meier plotter mRNA breast cancer database was applied to evaluate the prognostic values of hub genes in breast cancer patients, especially in TNBC patients. In our study, TNBC patients were screened out based on ER, PR, and HER-2 negative expression. Probes of genes were selected based on the "only JetSet best probe set," and the desired probe IDs for each gene are shown in [Table S1](#SD1-ott-11-4105){ref-type="supplementary-material"}. For each gene, cancer patients were divided into two groups according to the median values of mRNA expression. *P*\<0.01 was considered to indicate a statistically significant result.

Results
=======

Identification of DEGs
----------------------

Three gene expression profiles (GSE38959, GSE45827, and GSE65194) were selected in this study. Among them, GSE38959 contained 30 TNBC samples and 13 normal samples, and GSE45827 and GSE65194 included 41 TNBC specimens and eleven normal breast specimens respectively ([Table 1](#t1-ott-11-4105){ref-type="table"}). Based on the criteria of *P*\<0.05 and \|logFC\|≥2, a total of 852 DEGs were identified from GSE38959, including 515 upregulated genes and 337 downregulated genes. In gene chip GSE45827, 2,995 DEGs were identified; 2,117 genes were upregulated, and 878 genes were downregulated. And from GSE65194, 3,031 DEGs including 2,130 upregulated genes and 901 downregulated genes were identified. All DEGs were identified by comparing TNBC samples with normal breast samples. Subsequently, Venn analysis was performed to get the intersection of the DEG profiles ([Figure 1](#f1-ott-11-4105){ref-type="fig"}). Finally, 451 DEGs were significantly differentially expressed among all three groups, of which 278 were significantly upregulated genes and 173 were downregulated.

Functional enrichment analyses of DEGs
--------------------------------------

GO function and KEGG pathway enrichment analysis for DEGs were performed using the DAVID ([Table 2](#t2-ott-11-4105){ref-type="table"}). The enriched GO terms were divided into CC, BP, and MF ontologies. The results of GO analysis indicated that DEGs were mainly enriched in BPs, including sister chromatid cohesion, microtubule-based movement, anaphase-promoting complex-dependent catabolic process, and extracellular matrix (ECM) organization. MF analysis showed that the DEGs were significantly enriched in microtubule binding, transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding, ATPase activity, and microtubule motor activity. For the cell component, the DEGs were enriched in condensed chromosome kinetochore, microtubule, kinetochore, and spindle. In addition, the results of KEGG pathway analysis showed that DEGs were mainly enriched in pathways in cancer, small cell lung cancer, and ECM--receptor interaction.

PPI network construction and hub gene identification
----------------------------------------------------

Protein interactions among the DEGs were predicted with STRING tools. A total of 111 nodes and 1,365 edges were involved in the PPI network, as presented in [Figure 2](#f2-ott-11-4105){ref-type="fig"}. The top ten genes evaluated by connectivity degree in the PPI network were identified ([Table 3](#t3-ott-11-4105){ref-type="table"}). The results showed that cyclin-dependent kinases 1 (*CDK1*) was the most outstanding gene with connectivity degree=64, followed by cyclin B1 (*CCNB1*; degree=61), baculoviral IAP repeat containing 5 (*BIRC5*; degree=60), aurora kinase A (*AURKA*; degree=58), polo-like kinase 1 (*PLK1*; degree=56), mitotic arrest deficient 2-like 1 (*MAD2L1*; degree=54), BUB1 mitotic checkpoint serine/threonine kinase B (*BUB1B*; degree=54), nuclear division cycle 80 (*NDC80*; degree=53), budding uninhibited by benzimidazoles 1 (*BUB1*; degree=52), and kinesin family member 11 (*KIF11*; degree=52). All of these hub genes were upregulated in TNBC.

Survival analysis of ten hub genes
----------------------------------

To investigate the prognostic values of the ten potential hub genes, the Kaplan--Meier plotter bioinformatics analysis platform was used. A total of 1,402 breast cancer patients were available for the analysis of overall survival. We found that high expression of these hub genes was associated with unfavorable overall survival of breast cancer patients ([Figure 3](#f3-ott-11-4105){ref-type="fig"}).

However, only overexpression of *CCNB1* was an unfavorable prognostic factor of relapse-free survival in TNBC patients (HR=2.12; 95% CI: 1.2--3.72; *P*=0.0078; n=255). There were not enough incidents for overall survival analysis ([Figure 4](#f4-ott-11-4105){ref-type="fig"}).

Discussion
==========

Breast cancer is a heterogeneous disease, and the histopathological features and clinical behaviors are distinct among subtypes. TNBC is a unique subtype of breast cancer with poor prognosis. Patients with TNBC have an increased likelihood of relapse and visceral metastasis. Due to lacking a therapeutic target, patients with TNBC could not benefit from endocrine therapy or HER2-targeted therapy, and chemotherapy is currently the mainstay of adjuvant treatment. However, TNBC patients are more likely to develop chemoresistance. Hence, it is crucial to identify new specific targeted therapies for TNBC.

In the present study, gene expression and protein--protein expression analysis based on publicly available databases was performed to identify potential key genes correlated with TNBC. DEGs between TNBC and healthy human breast tissue were screened out based on gene expression profiling data from the GEO database. Totally, we identified 278 upregulated DEGs and 173 downregulated DEGs. These DEGs were associated with the GO BP terms such as condensed chromosome kinetochore, sister chromatid cohesion, kinetochore, and microtubule binding, and significantly enriched in the KEGG terms small cell lung cancer, pathways in cancer, and ECM--receptor interaction. A PPI network was constructed to investigate the interrelationship of the DEGs, and ten hub genes were identified, including *AURKA*, *BIRC5*, *BUB1B*, *BUB1*, *CCNB1*, *CDK1*, *KIF11*, *MAD2L1*, *NDC80*, and *PLK1*. All of these genes were upregulated in TNBC. Finally, the Kaplan--Meier plotter online tool was applied to predict the relationship between the expression of hub genes and prognosis of TNBC patients. Based on the Kaplan--Meier plotter, overexpression of all the above genes was related to unfavorable prognosis of breast cancer patients. However, only overexpression of *CCNB1* was an unfavorable prognostic factor of TNBC patients.

*CCNB1*, also known as cyclin B1, is a key modulator in controlling cell proliferation.[@b8-ott-11-4105] Some research has demonstrated that *CCNB1* is involved in apoptosis, chemoresistance, and epithelial mesenchymal transitions of tumor cells.[@b9-ott-11-4105],[@b10-ott-11-4105] Overexpression of cyclin B1 has been reported in many tumors, such as colorectal cancer, gastric cancer,[@b11-ott-11-4105] pancreatic carcinoma,[@b12-ott-11-4105] and lung carcinoma.[@b13-ott-11-4105] Some of these studies suggested that the overexpression of cyclin B1 may be associated with the poor prognosis of these malignant diseases. For breast cancer, a lot of studies have shown that cyclin B1 overexpression was associated with aggressive clinical behaviors and was an independent prognostic factor. Aaltonen et al[@b14-ott-11-4105] showed that cyclin B1 overexpression was correlated with an aggressive phenotype and was significantly associated with shorter overall survival and metastasis-free survival in breast cancer patients. Ding et al[@b15-ott-11-4105] reported that a high level of CCNB1 was closely associated with hormone therapy resistance and poor recurrence-free survival, disease-free survival, and distant metastasis-free survival of ER+ breast cancer patients. And a meta-analysis by Sun et al[@b16-ott-11-4105] suggested that cyclin B1 overexpression might be an independent potential prognostic marker for disease-specific survival and disease-free survival of breast cancer. TNBC are usually high grade tumors with primitive features, suggesting that cyclin B1 may overexpress in TNBC. Agarwal et al[@b17-ott-11-4105] reported that cyclin B1 was expressed at a significantly higher level in TNBC cell lines than other subtypes. In our study, cyclin B1 was overexpressed in TNBC compared to normal breast tissue, and overexpression of cyclin B1 was correlated with unfavorable relapse-free survival of TNBC patients. Therefore, cyclin B1 may be a prognostic factor and potential therapeutic target for TNBCs.

Except for *CCNB1*, we detected other nine hub genes associated with breast cancer, including *CDK1*, *AURKA*, *BIRC5*, *MAD2L1*, *BUB1B*, *BUB1*, *PLK1*, *KIF11*, and *NDC80*. Most of them were reported as an essential factor involved in cell division and proliferation. Proteins encoded by *AURKA*, *BUB1*, *BUB1B*, *PLK1*, and *CDK1* are all serine/threonine kinases involved in the regulation of the cell cycle,[@b18-ott-11-4105] and overexpression of these genes has been detected in various human cancers and correlated with their prognosis. Roylance et al[@b19-ott-11-4105] reported that a high *AURKA* expression level was significantly associated with poorer clinical outcome in breast cancer patients. In Sotiriou et al's study,[@b20-ott-11-4105] *BUB1* was upregulated and correlated with a poor clinical prognosis in breast cancer patients. Many studies have shown an association between *PLK1* overexpression and poor clinical prognosis, and suggested that inhibition of *PLK1* may be a potential therapy for cancer treatment.[@b21-ott-11-4105],[@b22-ott-11-4105] For *CDK1*, many research studies have reported its overexpression in cancers and that it acts as an adverse prognostic factor, and many kinds of CDK inhibitors have been developed.[@b23-ott-11-4105]

In our study, *BIRC5*, *KIF11*, *MAD2L1*, and *NDC80* were overexpressed in breast cancer compared to normal breast tissues, and overexpression of these genes was significantly correlated with unfavorable clinical outcome in breast cancer patients. The results of our research were consistent with other studies.[@b24-ott-11-4105]--[@b27-ott-11-4105] However, the role of these genes in TNBC is not clear and further study is needed.

Conclusion
==========

Our bioinformatics analysis identified 451 DEGs between TNBCs and normal breast tissues based on the gene expression datasets obtained from the GEO database. Among them, ten hub genes might be the core genes of breast cancer, including *AURKA*, *BIRC5*, *BUB1B*, *BUB1*, *CCNB1*, *CDK1*, *KIF11*, *MAD2L1*, *NDC80*, and *PLK1*. All of them were upregulated in breast cancer, and overexpression of these genes was associated with unfavorable clinical outcome in breast cancer patients. In TNBC patients, *CCNB1* overexpression is an unfavorable prognostic factor. Further study is needed to confirm the results of our research. Anyway, *CCNB1* may be a potential target for TNBC therapy.

Supplementary material
======================

###### 

The desired probes of hub genes in the Kaplan--Meier plotter database

  Gene symbol   Probe ID
  ------------- --------------
  *CDK1*        203213_at
  *CCNB1*       228729_at
  *BIRC5*       202094_at
  *AURKA*       208079_s\_at
  *PLK1*        202240_at
  *MAD2L1*      203362_s\_at
  *BUB1B*       203755_at
  *NDC80*       204162_at
  *BUB1*        209642_at
  *KIF11*       204444_at
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![Venn diagram of DEGs common to all three GEO datasets.\
**Notes:** (**A**) Downregulated genes. (**B**) Upregulated genes.\
**Abbreviations:** DEG, differentially expressed gene; GEO, Gene Expression Omnibus.](ott-11-4105Fig1){#f1-ott-11-4105}

![Protein--protein interaction network constructed with the differentially expressed genes.\
**Note:** Red nodes represent upregulated genes, and blue nodes represent downregulated genes.](ott-11-4105Fig2){#f2-ott-11-4105}

![Kaplan--Meier overall survival analyses for the top ten hub genes expressed in breast cancer patients.\
**Note:** See [Table 3](#t3-ott-11-4105){ref-type="table"} for gene description.](ott-11-4105Fig3){#f3-ott-11-4105}

![Kaplan--Meier relapse-free survival analyses for *CCNB1* expression in TNBC patients.\
**Abbreviations:** *CCNB1* cyclin B1; TNBC, triple-negative breast cancer.](ott-11-4105Fig4){#f4-ott-11-4105}

###### 

Statistics of the three microarray databases derived from the GEO database

  Dataset ID   TNBC   Normal   Total number
  ------------ ------ -------- --------------
  GSE38959     30     13       43
  GSE45827     41     11       52
  GSE65194     41     11       52

**Abbreviations:** GEO, Gene Expression Omnibus; TNBC, triple-negative breast cancer.

###### 

Significantly enriched GO terms and KEGG pathways of DEGs

  Category       Term         Description                                                                                                     Count   *P*-value
  -------------- ------------ --------------------------------------------------------------------------------------------------------------- ------- -----------
  BP term        GO:0007062   Sister chromatid cohesion                                                                                       23      4.30E--15
  BP term        GO:0007018   Microtubule-based movement                                                                                      11      2.59E--05
  BP term        GO:0031145   Anaphase-promoting complex-dependent catabolic process                                                          10      1.24E--04
  BP term        GO:0030198   ECM organization                                                                                                14      1.03E--03
  CC term        GO:0000777   Condensed chromosome kinetochore                                                                                23      6.49E--17
  CC term        GO:0000776   Kinetochore                                                                                                     17      7.09E--11
  CC term        GO:0005819   Spindle                                                                                                         14      6.63E--06
  CC term        GO:0005874   Microtubule                                                                                                     19      5.31E--04
  MF term        GO:0008017   Microtubule binding                                                                                             20      7.71E--07
  MF term        GO:0003777   Microtubule motor activity                                                                                      11      2.27E--05
  MF term        GO:0001077   Transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding   15      1.90E--03
  MF term        GO:0016887   ATPase activity                                                                                                 12      5.11E--03
  KEGG pathway   hsa05222     Small cell lung cancer                                                                                          11      1.76E--04
  KEGG pathway   hsa05200     Pathways in cancer                                                                                              26      1.95E--04
  KEGG pathway   hsa04512     ECM--receptor interaction                                                                                       11      2.14E--04

**Abbreviations:** BP, biological process; CC, cellular component; DEG, differentially expressed gene; ECM, extracellular matrix; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function.

###### 

Top ten hub genes with higher degree of connectivity

  Gene symbol   Gene description                                    Degree
  ------------- --------------------------------------------------- --------
  *CDK1*        Cyclin-dependent kinases 1                          64
  *CCNB1*       Cyclin B1                                           61
  *BIRC5*       Baculoviral IAP repeat containing 5                 60
  *AURKA*       Aurora kinase A                                     58
  *PLK1*        Polo-like kinase 1                                  56
  *MAD2L1*      Mitotic arrest deficient 2-like 1                   54
  *BUB1B*       BUB1 mitotic checkpoint serine/threonine kinase B   54
  *NDC80*       Nuclear division cycle 80                           53
  *BUB1*        Budding uninhibited by benzimidazoles 1             52
  *KIF11*       Kinesin family member 11                            52
